Holen Sie sich die Stockscreener-App
57.69
0.28%
0.2073
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$57.48
Offen:
$58.22
24-Stunden-Volumen:
2.23M
Relative Volume:
0.16
Marktkapitalisierung:
$117.32B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
16.68
EPS:
3.4587
Netto-Cashflow:
$12.85B
1W Leistung:
-3.46%
1M Leistung:
-5.89%
6M Leistung:
+28.35%
1J Leistung:
-5.61%
1-Tages-Spanne:
$57.11
$58.25
1-Wochen-Bereich:
$56.91
$60.80
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.61 | 117.06B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
919.64 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.07 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.06 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
185.25 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
116.06 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers (BMY) Partnership Enhances Oxford Biomedica's Outl - GuruFocus
AI ECGs found 11 hidden heart disease cases and brought patients back to care - Stock Titan
Bristol Myers (BMY) Unveils New Data at 2026 ACC Conference - GuruFocus
insitro expands Bristol Myers Squibb ALS collaboration - Investing.com
AI drug discovery deal widens as Bristol Myers adds 2 ALS targets - Stock Titan
Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
TABR Capital Management LLC Invests $1.62 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers heart drug shows Phase 3 benefit in adolescents with oHCM - Stock Titan
Bristol Myers wins FDA approval for Opdivo in first-line Hodgkin lymphoma - MSN
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NorthCrest Asset Manangement LLC Purchases 36,677 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb: A Defensive Dividend Stock for Volatile MarketsNews and Statistics - IndexBox
A Look At Bristol Myers Squibb (BMY) Valuation As Recent Results Shape Growth And Cost Outlook - simplywall.st
IAM Advisory LLC Takes $1.66 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
20,156 Shares in Bristol Myers Squibb Company $BMY Purchased by MFG Wealth Management Inc. - MarketBeat
CWA Asset Management Group LLC Sells 35,291 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock faces pressure after earnings miss and cautious FY2026 guidance amid pipe - AD HOC NEWS
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. - PharmiWeb.com
Bristol Myers (BMY): New Approvals for Opdivo Expand Treatment O - GuruFocus
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) - Business Wire
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol Myers Squibb (BMY) Gains FDA Approval for Expanded Use o - GuruFocus
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Benzinga
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Benzinga
Bristol Myers wins FDA label expansion for Opdivo (BMY:NYSE) - Seeking Alpha
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters
Here is what to know beyond why Bristol Myers Squibb Company (BMY) is a trending stock - MSN
Top Stock Picks of 2026: Bristol-Myers Squibb - Schaeffer's Investment Research
CIBC Bancorp USA Inc. Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth - simplywall.st
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Swiss Life Asset Management Ltd Purchases 68,565 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Wilmington Savings Fund Society FSB Has $5.24 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - The Joplin Globe
Bristol-Myers Squibb Co Stock (ISIN: US1101221083) Faces Mixed Signals After Q4 Earnings Miss Amid S - AD HOC NEWS
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Eagle-Tribune
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists - Fierce Pharma
Merck vs. Bristol Myers: Which pharma stock is a better pick in 2026? - MSN
WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
US FDA approves J&J's oral psoriasis pill - Reuters
Danske Bank A S Makes New $71.59 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stake Boosted by Achmea Investment Management B.V. - MarketBeat
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthritis? - FirstWord Pharma
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study - TipRanks
Jefferies raises Bristol-Myers Squibb stock price target on trial data - Investing.com India
Jefferies raises Bristol-Myers Squibb stock price target on trial data By Investing.com - Investing.com South Africa
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60 - 富途牛牛
Bristol Myers Squibb Company $BMY Stock Position Increased by Gotham Asset Management LLC - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):